menu
    • menu
    [{"orgOrder":0,"company":"Lidds","sponsor":"Uppsala University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Uppsala University","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Uppsala University"},{"orgOrder":0,"company":"Lidds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Undisclosed"},{"orgOrder":0,"company":"Lidds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Undisclosed"},{"orgOrder":0,"company":"Lidds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Undisclosed"},{"orgOrder":0,"company":"Lidds","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Nice & Green"},{"orgOrder":0,"company":"Lidds","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lidds \/ CMX Research","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ CMX Research"}]

    Find Clinical Drug Pipeline Developments & Deals for 2-Hydroxyflutamide

    Menu

    2-Hydroxyflutamide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Nice & Green

                            Deal Size : $4.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LIDDS Secures Financing of Up To 40.8 MSEK to Create Foundation for New Partnerships Based on The NanoZolid® ...

                            Details : Proceeds drawn by LIDDS under the convertible notes agreement will be used to further advance the project in clinical development, creating a solid foundation for new partnerships and license agreements for Liproca, based on the NanoZolid® technology.

                            Product Name : Liproca Depot

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 22, 2022

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Nice & Green

                            Deal Size : $4.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Urology Focus Has Accepted a Scientific Article Describing LIDDS Phase IIb Study Results with Liproca...

                            Details : The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.

                            Product Name : Liproca Depot

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2021

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LIDDS Announces Data on Liproca Depot from Open Label Extension Study

                            Details : In patients who received a second Liproca® Depot injection (6 of 12), at 2 months post treatment, PSA levels were in average reduced by 28 %.

                            Product Name : Liproca Depot

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2020

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Liproca Phase II b Study Results Indicate Cancer Control

                            Details : Final data from the LPC-004 study confirms Liproca® Depot’s potential as a safe and effective anti-androgen treatment for prostate cancer patients that currently are not treated but kept under ‘Active Surveillance’.

                            Product Name : Liproca Depot

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2020

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CMX Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Pr...

                            Details : 2-Hydroxyflutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 21, 2017

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CMX Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lidds

                            Sweden arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Uppsala University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate ...

                            Details : 2-Hydroxyflutamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2015

                            Lead Product(s) : 2-Hydroxyflutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Uppsala University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth